Compare SILC & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SILC | PROF |
|---|---|---|
| Founded | 1987 | N/A |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.6M | 248.8M |
| IPO Year | 2002 | 2017 |
| Metric | SILC | PROF |
|---|---|---|
| Price | $48.58 | $5.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 164.7K | 117.9K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,098,000.00 |
| Revenue This Year | $17.17 | $92.40 |
| Revenue Next Year | $12.28 | $64.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $13.34 | $4.86 |
| 52 Week High | $52.95 | $8.95 |
| Indicator | SILC | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 60.80 | 39.29 |
| Support Level | $38.57 | $5.92 |
| Resistance Level | $52.52 | $6.06 |
| Average True Range (ATR) | 2.56 | 0.33 |
| MACD | 0.88 | -0.02 |
| Stochastic Oscillator | 86.45 | 34.25 |
Silicom Ltd is engaged in designing, manufacturing, marketing, and supporting high-performance networking and data infrastructure solutions for a broad range of servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, Switches, Edge AI Solutions, Edge Networking Accessories, 4G 5G Products, FPGA-Based Cards, and Others. Its geographic areas are the USA, North America - other, Israel, Europe, and Asia-Pacific. It derives a majority of its revenue from the USA.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.